Skip Navigation

Cardiovascular Research 2006 71(3):408-410; doi:10.1016/j.cardiores.2006.06.007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Davidson, S. M.
Right arrow Articles by Yellon, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davidson, S. M.
Right arrow Articles by Yellon, D. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2006, European Society of Cardiology

Dissecting out the mechanism of cardioprotection by endogenous erthyropoietin using genetic engineering

Sean M. Davidson and Derek M. Yellon*

The Hatter Cardiovascular Institute, Royal Free and University College Medical School, Department of Medicine, 67 Chenies Mews, University College Hospital, London WC1E 6HX, United Kingdom

* Corresponding author. Tel.: +44 207 380 9591; fax: +44 207 388 5095. Email address: d.yellon@ucl.ac.uk

Received 30 May 2006; accepted 6 June 2006

The first 10% of the full text of this article appears below.

See article by Tada et al. [2] (pages 466–477) in this issue.

Erythropoietin (EPO), as the name suggests, was first discovered as a cytokine for red blood cells, but as is so often the case, turns out to have other highly interesting physiological effects. It is produced primarily in the kidneys, and its synthesis increases in response to a decrease in blood oxygen levels. In 1989, the use of recombinant EPO was approved for the treatment of anemia resulting from chronic renal failure. Anemia also occurs quite frequently in patients with chronic heart failure, and may be an independent risk factor for adverse outcomes [1]. Preliminary data suggests that treatment with EPO may improve symptoms . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?